Vasquez, Elena

Optimal adjuvant endocrine therapy duration — 5 vs. 10 years of tamoxifen/AI given intermediate recurrence risk.

Brain metastasis management with tucatinib-based regimen vs. SRS.

41-year-old BRCA2 carrier with triple-negative breast cancer, completed neoadjuvant pembrolizumab + carboplatin/paclitaxel followed by AC with pCR. Adjuvant strategy: continue pembrolizumab per KEYNOTE-522, add olaparib per OlympiA, or both?

41-year-old BRCA2 carrier with triple-negative breast cancer, completed neoadjuvant pembrolizumab + carboplatin/paclitaxel followed by AC with pCR. Adjuvant strategy discussion: continue pembrolizumab per KEYNOTE-522, add olaparib per OlympiA, or both? Address sequencing and overlapping toxicity concerns.

Adjuvant capecitabine after neoadjuvant chemotherapy with residual disease.

Neoadjuvant immunotherapy (pembrolizumab) regimen selection with BRCA mutation status.

Role of sacituzumab govitecan in metastatic setting after progression on immunotherapy.

Role of sacituzumab govitecan in metastatic setting after progression on immunotherapy.

PARP inhibitor eligibility assessment for BRCA-mutated TNBC after neoadjuvant therapy.

PARP inhibitor eligibility assessment for BRCA-mutated TNBC after neoadjuvant therapy.

Adjuvant capecitabine after neoadjuvant chemotherapy with residual disease.

Neoadjuvant immunotherapy (pembrolizumab) regimen selection with BRCA mutation status.

Adjuvant capecitabine after neoadjuvant chemotherapy with residual disease.

Role of sacituzumab govitecan in metastatic setting after progression on immunotherapy.